The initiation of coverage by HC Wainwright & Co. with a Buy rating and a significant price target suggests a strong positive outlook for Cardiol Therapeutics. This endorsement from a reputable analyst firm can lead to increased investor confidence and potentially drive the stock price up in the short term.